| Field | Specification |
|---|---|
| Organism | |
| Applications | |
| Tissue | |
| Disease | Normal tissue |
| Growth properties | |
| Biosafety level | |
| Product format | Frozen |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Overview
Human Fetal Liver-CD34+ Progenitor Cells are human frozen primary cells from liver used for tissue-relevant cell biology, phenotypic characterization, and in vitro assay development. These cells display suspension, round growth characteristics.
Key elements and design rationale
- Biological source: Human (H. sapiens)
- Tissue origin: Liver
- Growth properties: Suspension, round
- Format: Frozen
- Reported expression/markers: CD34 (stem cell)
- Donor history: Normal tissue
- Biosafety level: II
Primary cells provide a biologically relevant starting point for in vitro studies because they retain tissue-linked morphology, growth behavior, and donor-associated characteristics that are often reduced in immortalized systems.
Research relevance and current trends
- Primary-cell models continue to be used when donor context, tissue specificity, and physiologic responsiveness are important.
- Researchers often combine primary cells with co-culture, matrix, or conditioned-media approaches to better reflect native microenvironments.
- Phenotypic characterization and careful tracking of culture conditions remain important for reproducible interpretation.
Common research applications
- Use in tissue-relevant in vitro assays where morphology and donor context matter.
- Measure phenotype, marker expression, or response to defined perturbations over time.
- Incorporate into co-culture or screening workflows requiring primary-cell context.
Product-specific data supplied for this listing
- Growth Conditions: PriCoat™ T25 Flasks (G299) are recommended for optimal cell culture. PriGrow X Series Medium (TM4066) + 1% Penicillin/Streptomycin Solution (G255), 37.0°C, 5% CO₂.Note: cells can be maintained in culture for up to 7 days.
- Warranty: abm warrants that cell lines shall be viable upon initiation of culture for a period of thirty (30) days after shipment and that they shall meet the specifications on the applicable abm Material Product Information sheet, certificate of analysis, and/or catalog description. Such thirty (30) day period is referred to herein as the "Warranty Period”.
Notes for experimental interpretation
- Primary cells can show donor-dependent and passage-dependent variation, so morphology, growth rate, and marker expression should be interpreted in the context of the specific lot and culture history.
- Attachment matrix, medium formulation, and gas conditions can materially influence phenotype maintenance and experimental readouts; use the recommended culture system where possible.
- Cryopreserved recovery conditions matter for viability and downstream behavior. We recommend using serum-free CryoGuard™ Freezing Media (TM078).
- Marker panels should be interpreted together with morphology and functional readouts rather than as a standalone identity measure.
- Thaw cells quickly in a 37°C water bath while agitating gently (maximum 90 seconds). The vial cap should be kept above the water level to minimize the risk of contamination.
- Decontaminate the vial by spraying and wiping the exterior of the vial with 70% ethanol. From this point onwards, all operations should be strictly carried out inside a biological safety cabinet using aseptic conditions.
- Transfer the cell suspension into a 15ml sterile conical tube containing 5ml of pre-warmed, complete growth media. Centrifuge cells at 400xg for 10 minutes.
- Aspirate the supernatant without disturbing the cell pellet. Re-suspend the cell pellet in the recommended pre-warmed, complete growth media and dispense into a T25 culture flask.
- Incubate the cells at the recommended conditions.
- Change medium with fresh growth medium every other day by repeating steps 3-5.
- Cells can be cultured for up to 7 days.
Cell line sourcing and selection (species, tissue, and disease model matching) · Stable cell line engineering (overexpression, knockdown, knockout via CRISPR/Cas9, shRNA, sgRNA) · Reporter gene integration (GFP, RFP, luciferase, fluorescent/bioluminescent constructs) · Genome editing and knockin (point mutations, tagged endogenous proteins, conditional alleles) · Inducible expression systems (Tet-On/Off and regulatable constructs) · Drug resistance marker selection (puromycin, G418, hygromycin, and others) · Custom growth and media optimisation for specific assay requirements · Scale-up production for high-throughput screening campaigns · Authentication and QC services (STR profiling, mycoplasma testing, viability assessment). Talk to a Scientist or contact support@biohippo.com.
